Answers are grounded in this paper and cite their sources.
This fibroblast growth factor-23 (FGF-23) has been found as a circulating hormone and pathogenic factor in many disease conditions. This review focuses on recent advances in FGF-23 as a therapeutic target, including fibroblast growth factor receptors (FGFR) tyrosine kinase inhibitor, FGF-23 antibody, FGF-23 C-terminal peptide, CYP24A1 inhibitor, and FGF-23 antagonist. We also update the advantages and disadvantages of targeting upstream and downstream molecules in FGF-23 signaling pathways.
No takes yet. Share an insight, caveat, or question.
Li et al. (2018) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: